vs

Side-by-side financial comparison of Origin Bancorp, Inc. (OBK) and RIGEL PHARMACEUTICALS INC (RIGL). Click either name above to swap in a different company.

Origin Bancorp, Inc. is the larger business by last-quarter revenue ($104.0M vs $69.8M, roughly 1.5× RIGEL PHARMACEUTICALS INC). RIGEL PHARMACEUTICALS INC runs the higher net margin — 384.0% vs 26.6%, a 357.4% gap on every dollar of revenue. Over the past eight quarters, RIGEL PHARMACEUTICALS INC's revenue compounded faster (53.7% CAGR vs 3.9%).

Southern Bancorp is a community development financial institution headquartered in Arkadelphia, Arkansas. It was founded in 1986 as Southern Development Bancorporation, and is often referred to simply as "Southern".

Rigel Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing and commercializing targeted small molecule therapies for autoimmune, inflammatory, and hematologic diseases. Its approved flagship product treats adult immune thrombocytopenia, with primary operations and core markets in the United States, addressing unmet medical needs for underserved patient groups.

OBK vs RIGL — Head-to-Head

Bigger by revenue
OBK
OBK
1.5× larger
OBK
$104.0M
$69.8M
RIGL
Higher net margin
RIGL
RIGL
357.4% more per $
RIGL
384.0%
26.6%
OBK
Faster 2-yr revenue CAGR
RIGL
RIGL
Annualised
RIGL
53.7%
3.9%
OBK

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
OBK
OBK
RIGL
RIGL
Revenue
$104.0M
$69.8M
Net Profit
$27.7M
$268.1M
Gross Margin
91.5%
Operating Margin
33.2%
Net Margin
26.6%
384.0%
Revenue YoY
21.2%
Net Profit YoY
1769.2%
EPS (diluted)
$0.89
$14.11

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
OBK
OBK
RIGL
RIGL
Q1 26
$104.0M
Q4 25
$103.4M
$69.8M
Q3 25
$109.8M
$69.5M
Q2 25
$83.5M
$101.7M
Q1 25
$94.1M
$53.3M
Q4 24
$78.3M
$57.6M
Q3 24
$90.8M
$55.3M
Q2 24
$96.4M
$36.8M
Net Profit
OBK
OBK
RIGL
RIGL
Q1 26
$27.7M
Q4 25
$29.5M
$268.1M
Q3 25
$8.6M
$27.9M
Q2 25
$14.6M
$59.6M
Q1 25
$22.4M
$11.4M
Q4 24
$14.3M
$14.3M
Q3 24
$18.6M
$12.4M
Q2 24
$21.0M
$-1.0M
Gross Margin
OBK
OBK
RIGL
RIGL
Q1 26
Q4 25
91.5%
Q3 25
93.2%
Q2 25
95.6%
Q1 25
91.7%
Q4 24
89.9%
Q3 24
85.5%
Q2 24
92.4%
Operating Margin
OBK
OBK
RIGL
RIGL
Q1 26
Q4 25
36.2%
33.2%
Q3 25
10.0%
40.9%
Q2 25
22.3%
60.1%
Q1 25
30.4%
23.9%
Q4 24
23.0%
28.9%
Q3 24
26.1%
25.4%
Q2 24
27.7%
1.2%
Net Margin
OBK
OBK
RIGL
RIGL
Q1 26
26.6%
Q4 25
28.5%
384.0%
Q3 25
7.9%
40.2%
Q2 25
17.5%
58.6%
Q1 25
23.8%
21.5%
Q4 24
18.2%
24.9%
Q3 24
20.5%
22.5%
Q2 24
21.8%
-2.8%
EPS (diluted)
OBK
OBK
RIGL
RIGL
Q1 26
$0.89
Q4 25
$0.95
$14.11
Q3 25
$0.27
$1.46
Q2 25
$0.47
$3.28
Q1 25
$0.71
$0.63
Q4 24
$0.45
$0.82
Q3 24
$0.60
$0.70
Q2 24
$0.67
$-0.06

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
OBK
OBK
RIGL
RIGL
Cash + ST InvestmentsLiquidity on hand
$155.0M
Total DebtLower is stronger
$52.5M
Stockholders' EquityBook value
$1.3B
$391.5M
Total Assets
$10.2B
$513.6M
Debt / EquityLower = less leverage
0.13×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
OBK
OBK
RIGL
RIGL
Q1 26
Q4 25
$424.2M
$155.0M
Q3 25
$626.9M
$137.1M
Q2 25
$334.1M
$108.4M
Q1 25
$486.2M
$77.1M
Q4 24
$470.2M
$77.3M
Q3 24
$321.2M
$61.1M
Q2 24
$288.1M
$49.1M
Total Debt
OBK
OBK
RIGL
RIGL
Q1 26
Q4 25
$52.5M
Q3 25
$60.0M
Q2 25
$60.0M
Q1 25
$60.0M
Q4 24
$60.0M
Q3 24
$60.0M
Q2 24
$60.0M
Stockholders' Equity
OBK
OBK
RIGL
RIGL
Q1 26
$1.3B
Q4 25
$1.2B
$391.5M
Q3 25
$1.2B
$117.6M
Q2 25
$1.2B
$81.9M
Q1 25
$1.2B
$18.6M
Q4 24
$1.1B
$3.3M
Q3 24
$1.1B
$-14.6M
Q2 24
$1.1B
$-29.9M
Total Assets
OBK
OBK
RIGL
RIGL
Q1 26
$10.2B
Q4 25
$9.7B
$513.6M
Q3 25
$9.8B
$242.5M
Q2 25
$9.7B
$206.7M
Q1 25
$9.8B
$176.0M
Q4 24
$9.7B
$164.0M
Q3 24
$10.0B
$139.4M
Q2 24
$9.9B
$128.4M
Debt / Equity
OBK
OBK
RIGL
RIGL
Q1 26
Q4 25
0.13×
Q3 25
0.51×
Q2 25
0.73×
Q1 25
3.23×
Q4 24
18.25×
Q3 24
Q2 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
OBK
OBK
RIGL
RIGL
Operating Cash FlowLast quarter
$22.0M
Free Cash FlowOCF − Capex
FCF MarginFCF / Revenue
Capex IntensityCapex / Revenue
Cash ConversionOCF / Net Profit
0.08×
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
OBK
OBK
RIGL
RIGL
Q1 26
Q4 25
$158.9M
$22.0M
Q3 25
$59.3M
$24.0M
Q2 25
$20.6M
$30.5M
Q1 25
$35.6M
$-893.0K
Q4 24
$108.5M
$14.5M
Q3 24
$39.6M
$21.7M
Q2 24
$11.9M
$302.0K
Free Cash Flow
OBK
OBK
RIGL
RIGL
Q1 26
Q4 25
$151.1M
Q3 25
$56.8M
Q2 25
$19.6M
Q1 25
$34.8M
Q4 24
$86.4M
Q3 24
$32.2M
Q2 24
$6.5M
FCF Margin
OBK
OBK
RIGL
RIGL
Q1 26
Q4 25
146.0%
Q3 25
51.7%
Q2 25
23.5%
Q1 25
37.0%
Q4 24
110.3%
Q3 24
35.5%
Q2 24
6.8%
Capex Intensity
OBK
OBK
RIGL
RIGL
Q1 26
Q4 25
7.6%
Q3 25
2.3%
Q2 25
1.2%
Q1 25
0.8%
Q4 24
28.1%
Q3 24
8.1%
Q2 24
5.6%
Cash Conversion
OBK
OBK
RIGL
RIGL
Q1 26
Q4 25
5.38×
0.08×
Q3 25
6.88×
0.86×
Q2 25
1.41×
0.51×
Q1 25
1.59×
-0.08×
Q4 24
7.60×
1.01×
Q3 24
2.13×
1.75×
Q2 24
0.57×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

OBK
OBK

Net Interest Income$87.2M84%
Noninterest Income$16.8M16%

RIGL
RIGL

Segment breakdown not available.

Related Comparisons